A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Ivosidenib (Primary) ; Vorasidenib (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Biomarker; Pharmacodynamics
- Acronyms Window
- Sponsors Agios Pharmaceuticals
- 22 Nov 2019 Results published in Agios Pharmaceuticals Media Release (July 26, 2019 data cutoff)
- 22 Nov 2019 According to an Agios Pharmaceuticals media release, data from this study was featured in an oral presentation at the Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix.
- 30 Aug 2019 Planned End Date changed from 1 Sep 2020 to 1 May 2024.